New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
November 13 2023 - 7:00AM
Business Wire
Developed in Partnership with Healthcare
Professionals and Patients, Let’s Talk About LGSOC Provides
Information Related to the Biology, Diagnosis, Treatment, and
Patient Experience
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company
committed to advancing new medicines for patients with cancer,
today announced the launch of the new healthcare professional
component of Let’s Talk About LGSOC, designed to support clinicians
in the diagnosis and management of low-grade serous ovarian cancer
(LGSOC). Let’s Talk About LGSOC provides detailed information about
the unique clinical, histopathological, and molecular features of
LGSOC, current National Comprehensive Cancer Network® (NCCN®)
clinical practice guidelines and additional medical and scientific
information and resources.
LGSOC of the ovary, fallopian tubes, and peritoneum is a rare
tumor that commonly affects younger women, with a median age of
diagnosis between 45-55 years. For many patients, LGSOC symptoms
and treatment side effects have a long-lasting impact on physical
and mental health. To date, limited treatment options are available
for LGSOC and no treatments have yet been approved by regulatory
authorities specifically for the treatment of LGSOC with doctors
and patients often resorting to using treatments that may have
originally been developed for other tumors.
“LGSOC has only recently been classified as a separate disease
as compared to the more common high-grade serous ovarian cancer
(HGSOC) with different epidemiology, pathology, clinical
presentation, and outcomes. Furthermore, the fact that it is rare
and disproportionally affects younger women than its high-grade
counterpart means we need to ensure the healthcare community is
aware that this form of ovarian cancer can impact women at any age
and the management approach is not the same as for other ovarian
cancers,” said Premal Thaker, MD, David and Lynn Mutch
Distinguished Professor of Obstetrics & Gynecology at
Washington University School of Medicine. “Let’s Talk About LGSOC
has already become a valuable information hub for patients and I
believe this LGSOC specific website will be a tremendous resource
for healthcare professionals as we seek to provide better care for
our patients.”
LGSOC represents approximately 10% of all ovarian cancers with
an estimated 1,000 to 2,000 patients diagnosed each year with more
than 6,000 patients living with its impact in the United States and
80,000 worldwide. LGSOC is primarily driven by the RAS/MAPK
pathway, a key contributor to tumor development and progression.
The majority of patients with LGSOC are diagnosed with advanced
stage disease that has spread beyond its primary site. It is
relatively resistant to chemotherapy and highly recurrent. More
than eighty percent of people with LGSOC will have their cancer
come back after remission.
“At Verastem, we are committed to providing opportunities for
more education about LGSOC in partnership with the physician and
patient community,” said Louis Denis, MD, Chief Medical Officer at
Verastem Oncology. “In addition to our work to help deliver new
innovative treatment options for LGSOC, we aim to raise awareness
of this distinct and different form of ovarian cancer that is
under- researched and often misunderstood. We believe the addition
of this new healthcare professional component to Let’s Talk About
LGSOC will complement the progress we are making with the patient
initiative launched earlier this year and support better care for
women with LGSOC.”
For more information about the Let’s Talk About LGSOC, please
visit the healthcare professional site at
www.LetsTalkAboutLGSOC.com/hcp and www.LetsTalkAboutLGSOC.com for
the patient site.
About Low-Grade Serous Ovarian Cancer (LGSOC) LGSOC is a
highly recurrent, chemotherapy-resistant cancer, associated with
slow tumor growth and high mortality rate. An estimated 6,000 women
in the U.S. and 80,000 worldwide are living with this disease.
LGSOC is known to be driven by the RAS/MAPK pathway in
approximately 70% of patients. Mutations in the KRAS gene are
present in 30% of cases of LGSOC. LGSOC is most often diagnosed in
women between the ages of 45-55 years and has a median survival of
approximately ten years. The majority of patients experience severe
pain and complications as the disease progresses. There are no FDA
approved medicines and limited treatment options currently
available.
About Verastem Oncology Verastem Oncology (Nasdaq: VSTM) is a
development-stage biopharmaceutical company committed to the
development and commercialization of new medicines to improve the
lives of patients diagnosed with cancer. Our pipeline is focused on
novel small molecule drugs that inhibit critical signaling pathways
in cancer that promote cancer cell survival and tumor growth,
including RAF/MEK inhibition and focal adhesion kinase (FAK)
inhibition. For more information, please visit
www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113852336/en/
Media: Lisa Buffington Corporate Communications +1 (781)
292-4502 lbuffington@verastem.com
Investors: Ryan Porter Argot Partners +1 212-600-1902
ryan.porter@argotpartners.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Jul 2023 to Jul 2024